-
Posted by
Two Blokes Apr 17 -
Filed in
Stock
-
6 views
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership in obesity treatment. Orforglipron offers advantages over competitors including easier manufacturing, no liver safety signals, and simpler administration than Novo Nordisk's option. Lilly reported $13.5B Q4 revenue (+32% YoY), driven by Mounjaro and Zepbound, with 2025 guidance of $58-61B.
